Serum biomarkers for early detection of ovarian cancer;Translationale forschung in der gynäkologischen onkologie: Serum-tumormarker zur früherkennung des ovarialkarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 68, Issue 8, 2008, Pages 830-837

  Meinhold Heerlein, Ivo ^a,b   Brautigam K ^a   Bauerschlag, D O ^a   Maass, N ^a   Arnold, N ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Biomarker; Early detection; Ovarian cancer; Panel; Screening

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; KALLIKREIN; MATRILYSIN; OSTEOPONTIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ALGORITHM; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DNA MICROARRAY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EID: 51549117902     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038858     Document Type: Review

References (51)

1. Akahiro J, Konno R et al. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol 2004; 9: 42-46.
2. Bast Jr. RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21: 200-205
3. Bast Jr. RC, Feeney M et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337
4. Bast Jr. RC, Klug TL et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887
5. Bogen SA, Sompuram SR. Recent trends and advances in immunodiagnostics of solid tumors. BioDrugs 2004; 18: 387-398
6. Brakora KA, Lee H et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004; 93: 361-365
7. Canney PA, Moore M et al. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765-769
8. Crump C, McIntosh MW et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 2000; 9: 1107-1111
9. Dehari R, Kurman RJ, Logani S, Shih Ie M The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-1012
10. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002; 48: 1198-1205
11. Gagnon A, Ye B. Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 2008; 20: 9-13
12. Havrilesky LJ, Whitehead CM et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; epub ahead of print
13. Heintz AP, Odicino F et al. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6: 107-138
14. Hellstrom I, Raycraft J et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-3700
15. Helzlsouer KJ, Bush TL et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. Jama 1993; 269: 1123-1126
16. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-6918
17. Hogdall EV, Christensen L et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007; 104: 508-515
18. Hudson ME, Pozdnyakova I et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007; 104: 17494-17499
19. Jemal A, Siegel R et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130
20. Kenemans P, van Kamp GJ et al. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993; 39: 2509-2513
21. Kim JH, Skates SJ et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679
22. Kozak KR, Su F et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589-4596
23. Kurman RJ, Visvanathan K et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; 198: 351-356
24. Lopez MF, Mikulskis A et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 2007; 53: 1067-1074
25. Lu KH, Patterson AP et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291-3300
26. Luo LY, Katsaros D et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003; 63: 807-811
27. Meinhold-Heerlein I, Bauerschlag D et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24: 1053-1065
28. Meinhold-Heerlein I, Bauerschlag D et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 2007; 13: 458-466
29. Mok SC, Chao J et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-1464
30. Moore RG, Brown AK et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108: 402-408
31. Mor G, Visintin I et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 7677-7682
32. Nossov V, Amneus M et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008; epub ahead of print
33. Petricoin EF, Ardekani AM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577
34. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih Ie M. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000
35. Rai AJ, Zhang Z et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-1526
36. Rosen DG, Wang L et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277
37. Schorge JO, Drake RD et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10: 3474-3478
38. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518
39. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-7279
40. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486
41. Skates SJ, Menon U et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21: 206s-210s
42. Suzuki M, Ohwada M et al. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 1993; 82: 946-950
43. Tanimoto H, Underwood LJ et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999; 20: 88-98
44. Tsukishiro S, Suzumori N et al. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005; 96: 516-519
45. Visintin I, Feng Z et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-1072
46. Wang FQ, So J et al. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005; 114:19-31
47. Welsh JB, Zarrinkar PP et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001; 98: 1176-1181
48. Woolas RP, Conaway MR et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59: 111-116
49. Ye B, Cramer DW et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-2911
50. Zhang Z, Bast RC Jr. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890
51. Zurawski VR Jr., Orjaseter H et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42: 677-680